Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion type Assertion NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_head.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion description "[We therefore tested a rationally designed triple therapy consisting of an agonistic antibody against either TRAIL-R1 (mapatumumab/HGS-ETR1) or TRAIL-R2 (lexatumumab/HGS-ETR2) in combination with the established chemotherapeutic drug cisplatin in a panel of solid tumour cell lines derived from head and neck as well as colorectal carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_provenance.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion evidence source_evidence_literature NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_provenance.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion SIO_000772 19424623 NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_provenance.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion wasDerivedFrom befree-20140225 NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_provenance.
- NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_assertion wasGeneratedBy ECO_0000203 NP279779.RAdUslyzVVIy0oZS-VCdEVX9oam4KAxoTHLOOwbjE_Nb0130_provenance.